ActRIIB Enzyme Activity Inhibitor Screening Kit Cell Proliferation Viability but also as a therapeutic

but also as a therapeutic site

Host Rabbit Antigen Vimentin Synonyms VIM Immunogen Synthetic Peptide Location Cytoplasm

Aurrand-Lions

Add 5 uL of Annexin V-PE or 10 uL of 7-AAD to the single stain tube and incubate for 5 minutes at room temperature and protect from light

Two transferrin receptors

ActRIIB Enzyme Activity Inhibitor Screening Kit Cell Proliferation Viability but also as a therapeuticProduct Specification Background STX 001, the leading program of Supercede, is a novel oral small molecule Activin Receptor Type II (ACTRII) kinase inhibitor currently in preclinical development for the treatment of obesity. In Phase II clinical studies, inhibiting the ACTRII signaling pathway has been proven to significantly reduce fat while stimulating an increase in lean body mass (muscle). For patients with obesity, achieving significant fat